Proliferative mechanisms involving the epidermal growth factor (EGF) and transforming growth factor beta (TGF-b 1 ) ligands are potential alternative pathways for prostate cancer (PC) progression to androgen independence (AI). Thus, the combined effect of EGF and TGFB1 functional polymorphisms might modulate tumor microenvironment and consequently its development. We studied EGF þ 61G4A and TGFB1 þ 869T4C functional polymorphisms in 234 patients with PC and 243 healthy individuals. Intermediate-and highproliferation genetic profile carriers have increased risk for PC (odds ratio (OR) ¼ 3.76, P ¼ 0.007 and OR ¼ 3.98, P ¼ 0.004, respectively), when compared with low proliferation individuals. Multivariate analysis showed a significantly lower time to AI in the high proliferation group, compared with the low/intermediate proliferation genetic profile carriers (HR ¼ 2.67, P ¼ 0.039), after adjustment for age, metastasis and stage. Results suggest that combined analysis of target genetic polymorphisms may contribute to the definition of cancer susceptibility and pharmacogenomic profiles. Combined blockage of key molecules in proliferation signaling pathways could be one of the most promising strategies for androgen-independent prostate cancer.
Introduction
Prostate cancer (PC) is one of the most common malignancies among men in the Western world and a major health problem in many industrialized countries. 1 Despite recent advances in the detection of early PC there is little effective therapy for patients with locally advanced and/or metastatic disease. Patients diagnosed in advanced stages are frequently submitted to hormonal treatment with androgen deprivation therapy (ADT), 2 although most men will eventually fail this therapy and die from recurrent androgen-independent prostate cancer (AIPC). AIPC is an invariably lethal condition associated with significant deterioration of the quality of life. 3, 4 Therefore, it is important to understand the mechanisms involved in AI progression.
It is known that the androgen pathway has a critical role in the survival of prostatic cells; however, progression into advanced PC and incurable forms has been associated with the activation of other cascades mediated by growth factors responsible for the balance between cell growth rate and apoptosis. Cell proliferation is normally regulated by the concerted action of both mitogenic growth signals and antiproliferative signals that converge on regulators of the cell cycle. In fact, the prostate is known to be dependent not exclusively on androgens but also on growth factors. 5 Some authors suggest that aberrant growth and differentiation are because of inappropriate cellular environment. 6 The epidermal growth factor (EGF) and the transforming growth factor-beta 1 (TGF-b 1 ) are the key players, with opposite roles, in cell proliferation. EGF activates several pro-oncogenic intracellular pathways leading to proliferation, differentiation and tumorigenesis of epithelial cells. 7, 8 Cumulatively, its receptor (EGFR (epidermal growth factor receptor)) is proposed to participate in the pathogenesis and growth of several epithelial human cancers. In PC cells, EGFR ligands are frequently elevated and EGFR itself is commonly overexpressed. 9 Furthermore, EGFR expression increases during progression to AI. 10 Epidermal growth factor is encoded by the EGF gene, located on chromosome 4q25-q27. Shabazi et al.
11 identified a functional G4A single nucleotide polymorphism at position þ 61 in the 5 0 -untranslated region of the EGF gene (rs4444903). In vitro studies showed that G-carriers have an increased EGF production in both normal and tumoral cells. [11] [12] [13] This functional polymorphism has been associated with several malignancies, [11] [12] [13] [14] [15] including an earlier report from our group in PC. 16 Transforming growth factor-b 1 is a multifunctional regulatory polypeptide that controls many aspects of cellular function, such as cellular proliferation, differentiation, migration, apoptosis, adhesion, angiogenesis, immune surveillance and survival. 17 Nevertheless, TGF-b 1 has been suggested to play a dual role, acting as a suppressor in the early stages and as a tumor promoter in the later stages, by enhancing tumor cell motility and invasiveness. 18, 19 Recently, a functional polymorphism was described in TGFB1 gene (TGFB1 þ 869T4C), responsible for a T-to-C substitution at nucleotide 29 of codon 10 (rs1982073). This variant is located in the hydrophobic core of the signal peptide, resulting in the replacement of a hydrophobic leucine with a small, neutral proline. This transition has been associated with higher circulating levels of TGF-b 1 (in homozygous C). 20, 21 Genetic variants, which influence EGF and TGFB1 expressions and protein serum levels, may impact PC development and prognosis. Our purpose was to investigate the combination of EGF þ 61G4A and TGFB1 þ 869T4C functional polymorphisms in PC and AIPC in response to ADT.
Results
Using the recessive model, frequencies for homozygous AA and AG/GG genotypes of EGF þ 61G4A polymorphism were, respectively, 0.32 and 0.68 for PC patients and 0.34 and 0.66 in the control group. The TGFB1 þ 869T4C polymorphism frequencies for homozygous CC and CT/TT were 0.14 and 0.86 in PC group and 0.22 and 0.78 in the control group, respectively. Observed versus expected genotype frequencies were calculated, and no deviation from Hardy-Weinberg equilibrium was observed, except for the TGFB1 polymorphism in control group (EGF þ 61G4A: PC group, P ¼ 0.082, control group, P ¼ 0.073; TGFB1 þ 869T4C: PC group, P ¼ 0.761, control group, P ¼ 0.020).
High-and intermediate-proliferation genetic profiles' distributions were overrepresented in PC (0.56 and 0.42, respectively) and control (0.52 and 0.40, respectively) groups compared with the low-proliferation functional genetic profile ( The analysis of clinico-pathological characteristics according to the combined proliferation genetic profile showed no statistically significant associations of the combined polymorphisms with Gleason grade, distant metastasis and prostate specific antigen (PSA) at the time of diagnosis (P ¼ 0.319, P ¼ 0.572 and P ¼ 0.254, respectively).
Concerning AI-free interval after the beginning of ADT, we found a significantly reduced time-to-AI in highproliferation functional genetic profile carriers (93.99 (6.87) months in low/intermediate proliferation group and 76.51 (6.15) months in high proliferation group), using a multivariate Cox regression model with age (P ¼ 0.299), tumor stage (Po0.0001), surgery (P ¼ 0.982) and hormonal (Figure 1 ).
Discussion
The intricate balance between cell growth and proliferation factors versus apoptosis-inducing factors is mandatory for prostate growth regulation. Conversely, homeostatic disruptions in PC often trigger the loss of apoptosis and the overexpression of factors promoting cell survival and proliferation. A common deregulated mechanism in PC cells is distinguished by apoptotic evasion, uncontrolled proliferation and loss of differentiation. 17 Growth factors play a significant role in the growth of normal, hyperplastic and malignant prostatic epithelium. There is a significant amount of evidence supporting that the EGF and the transforming growth factor-beta (TGF-b) families are among the most relevant mediators of proliferation in this type of cancer. 22, 23 In line with these findings, our results suggest that TGF-b 1 and EGF combined effect may impact significantly in the individual PC risk, as well as in ADT outcome. However, a limitation to the study on PC susceptibility association with combined EGF and TGFB1 variants, resides in the significantly different mean age between PC and control groups, and the lack of information and subsequent adjustment for potentially relevant environmental factors. Therefore, conclusions on this issue should be interpreted cautiously owing to limitations inherent to the design.
Other line of evidence unfocused in target genes showed that in genome-wide association studies, [24] [25] [26] PC susceptibility loci do not reside within or near identifiable genes. It has been hypothesized that they exist in regulatory regions of DNA that control gene expression, or alternatively, in regions of DNA that code for microRNAs or other regulatory transcripts, as recently conceptualized by Glinsky. 27, 28 Ultimately, our results and these new lines of research will encourage future studies to increase our understanding of the biological basis of PC, providing an opportunity to design new therapies.
Several lines of evidence support the involvement of EGF in PC development. The normal and tumoral prostatic epithelium produces large amounts of EGF, 29 its receptor was found to be overexpressed in prostatic tumors, and the EGF/EGFR pathway has been associated with AI development. 9, 30 Cumulatively, it was shown that EGF and EGFR expression levels in PC cells are enhanced during disease progression to AI and metastatic PC. 10 Transforming growth factor-b 1 exerts a wide variety of biological actions, through both autocrine and paracrine mechanisms. It's role has been associated with advanced disease and metastasis, through the induction of extracellular proteolysis, angiogenesis and immune suppression. 31 However, in the earlier stages of tumor development TGF-b 1 can act as an inhibitor of tumor progression. 32 According to Tang et al., 33 the suppression of autocrine TGF-b 1 actions leads to the activation of tumorigenic properties. In fact, it was observed a dual role for TGF-b 1 in PC cells, with both an inhibitory or a stimulatory growth effect. 34 These apparently paradoxal findings can be attributed to TGF-b 1 concentration, which leads to proliferation in low TGF-b 1 environments, and induces growth arrest in the presence of high concentrations of TGF-b 1 . 35 This ligand that potentially inhibit epithelial, endothelial and hematopoietic cell proliferation, is able to prevent progression through the cell cycle by inducing expression of cyclin kinase inhibitors p15, p21 and p27. 17 Furthermore, it regulates the expression of several key proteins in the control of cell-cycle progression from G1-to-S phase, 17 including c-myc. It was shown that TGF-b 1 can rapidly inhibit the transcription of c-myc in epithelial cells. 36 TGF-b 1 is also produced in prostatic stromal cells, inducing apoptosis through a paracrine mechanism in prostate epithelial cell. In fact, it was already shown that the TGF-b signaling pathway may have prognostic significance in PC patients and that in vitro restoration of TGF-b 1 signaling pathway in PC cells inhibits proliferation. 37, 38 Case-control molecular epidemiology studies from our group and others have shown promising results concerning the development of molecular markers for PC susceptibility and aggressiveness. [39] [40] [41] [42] Specifically, it was hypothesized that functional polymorphisms with impact in growth factor and cytokine expression and circulating levels may influence individual susceptibility to PC, the response to treatment and prognosis significance.
The EGF þ 61G4A polymorphism encodes a significant functional difference in EGF expression. [11] [12] [13] Conversely, it is expected that G-carriers will have a higher EGF availability in tumoral environment. EGF þ 61G4A polymorphism has been the subject of investigation in case-control studies, involving other cancer types. [11] [12] [13] [14] [15] [16] Recently, we have shown that this functional polymorphism was associated with increased risk for PC, being diagnosed with aggressive disease and worst response to ADT. 16 The TGFB1 þ 869T4C functional polymorphism is responsible for significantly higher TGF-b 1 circulating levels in C-carriers and in vitro transfection experiments showed that the signal peptide in C-carriers caused a 2.8-fold increase in the secretion of TGF-b 1 compared with T-carriers. 43 The combined lower TGF-b 1 production in the presence of T-allele 21 and higher levels of EGF associated with the presence of G-allele, might contribute to a favorable longterm proliferative potential in prostate epithelial cells, which may increase PC risk.
Although interactions between cancer cells and the extracellular environment are important in processes such as invasion, angiogenesis and metastization, and TGF-b 1 and EGF are known to play a role in these mechanisms, 17,44 our results do not support this hypothesis. We suggest that, as we used a combined genetic profile of EGF and TGFB1 based on the proliferation phenotype, we were unable to find an association with aggressive PC.
Patients with local or distant metastatic PC are usually treated primarily through pharmacological androgen suppression. 2 This hormonal therapy is initially efficient, although the majority of patients will subsequently become unresponsive to androgen inhibition 45 and consequently the development of AIPC is a clinical problem of major concern. 2, 3 In fact, AIPC is a complex and heterogeneous form of PC with a high capacity of progression and metastization. 4 Conversely, the comprehension of molecular pathways underlying this disease is imperative.
The AIPC is a multistep/multievent process with different molecular patterns throughout development, involving changes in signaling pathways of growth suppressing or promoting factors. 46 It was hypothesized that EGF/EGFR and TGF-b 1 /TGF-b 1 RII pathways are involved in the acquisition of AIPC phenotype, either through an independent alternative proliferative stimulus, or through the interference with androgen receptor (AR) axis. 46, 47 The prostate is an androgen-dependent (AD) organ that undergoes involution after castration. Isaacs and Cooffey 48 suggested that the shift from AD-to-AIPC may be because of residual stem cells not responsive to androgens, which will emerge after ADT under the appropriate growth stimulus. It is well established that the microenvironment surrounding PC cells after ADT may play an important role in their behavior. Stem cells are usually quiescent and reside surrounded by a microenvironment that maintains the balance between quiescence and self-renewal stem cell population. TGF-b 1 and EGF have been implicated as modulators of stem cell proliferation, thereby regulating their homeostasis. 49 In addition to the proposed mechanism for EGF and TGF-b 1 in AI development, we suggest that by selecting AI cell clones, ADT creates an opportunity for these undifferentiated stem cells to grow according to the involving microenvironment. Accordingly, carriers of a high-proliferation constitutive genetic profile will likely be exposed to an increased proliferative stimulus, thus contributing to AI disease. However, the small sample size in our study may limit the ability to discern meaningful differences. Further research is needed to evaluate the associations reported here in more details. In particular large, well-designed studies of ethnically diverse populations and functional studies on PC cells may help clarify which variants are truly causal for this disease.
Present results support that combined analysis of genetic polymorphisms might reinforce the clinical capacity to predict the response to treatment. Furthermore, these findings also support the need of other studies to ascertain the therapeutic value of targeted-combined therapies directed against both EGF/EGFR and TGF-b 1 /TGF-b 1 RII pathways.
In summary, we observed a statistically significant increased risk for developing PC in EGF and TGFB1 combined high-and intermediate-proliferation functional genetic profile carriers. Cumulatively, the high-proliferation functional genetic profile carriers were more prone to develop AI.
Materials and methods

Study population
This case-control study was undertaken in 234 patients, with a mean age of 69.1 (7.48), with histopathologically diagnosed PC. The median follow-up time was 32 months (range 2.5-137 months). Patients distribution according to the stage at the time of diagnosis was 43.4% presenting localized disease (T 1 -T 2b ), 37.9% with locally advanced disease (T 3 -T 4 ) and 18.7% with metastatic disease (N þ and/or M þ ). The types of hormonal treatment were as follows: anti-androgens plus luteinizing hormonereleasing hormone agonists (aLHRH) combination therapy (81.7%); aLHRH alone (8.7%) and anti-androgens alone (9.6%). Hormone resistance was evaluated through PSA recurrence, which was defined as two consecutive increasing PSA values more than 1.0 ng ml À1 and differing by more than 0.2 ng ml À1 . Men older than 40 years of age, without known history of cancer were recruited from the Portuguese Institute of Oncology-Porto Centre Blood Donor's Bank and included in the control group (n ¼ 243), with a mean age of 44.7 (11.55). Study was conducted according to the Helsinki Declaration principles. A venous blood sample (8 ml) was obtained from each subject by forearm venipuncture. White cell fraction was used to extract DNA according to salting-out procedure. 50 EGF þ 61G4A and TGFB1 þ 869T4C genotyping The EGF þ 61G4A polymorphism was analyzed through polymerase chain reaction (PCR) followed by RFLP (restriction fragment length polymorphism), as described in earlier reports. 15, 16 Briefly, DNA was amplified in a 50-ml reaction mixture containing EGF þ 61G4A specific primers, PCR buffer 1 Â , Taq Polymerase 1 U, MgCl 2 1.5 mM, dNTPs 0.2 mM, DNA 100 ng. PCR products (242 bp) were incubated overnight with AluI restriction endonuclease at 37 1C. The restricted fragments were separated by electrophoresis on 3% agarose gels with ethidium bromide staining.
The polymorphism was defined by presence (A) or absence (G) of an additional restriction site.
The TGFB1 þ 869T4C polymorphism was analyzed by allelic discrimination using 7300 real-time PCR System (Applied Biosystems, Foster City, CA, USA). Real-time PCR were carried out using a 6-ml reaction mixture, containing 1 Â Master Mix (Applied Biosystems), with 1 Â probes (TaqMan assay C__22272997_10__, Applied Biosystems) and 90 ng of the DNA sample.
Quality control procedures implemented for genotyping included double sampling in about 10% of the samples to assess reliability and the use of negative controls to stepaway false-positives. In PCR-RFLP method, two authors obtained the results independently, and the ambiguous were reanalysed.
Statistical analysis
Genotypes of the two polymorphisms were combined into three categories according to the functional consequences in cell proliferation: low-, intermediate-and high-proliferation genetic profile ( Table 2 ). The rationale for defining highproliferation functional genetic profile was to associate the overexpressing G-allele from EGF þ 61G4A polymorphism with the T-allele from TGFB1 þ 869T4C variant related to lower TGF-b 1 production. In the intermediate-functional genetic profile, we have combined EGF þ 61G4A and TGFB1 þ 869T4C polymorphisms (AA plus CT/TT carriers, and AG/GG plus CC, respectively). The combination of EGF þ 61G4A homozygous A with TGFB1 þ 869T4C homozygous C polymorphism corresponded to the lowproliferation genetic profile.
Genetic profiles proportions among groups were compared using the Pearson's w 2 -test. OR and 95% confidence interval (CI) were calculated as a measure of association between EGF/TGFB1 combined genetic profiles in cases and controls. A Cox proportional hazard model was used to analyze the time to AI (determined by the interval of time since the beginning of ADT until AI or the last clinical visit), considering as covariates, age at diagnosis (X69 vs o69 years old), tumor stage (localized vs locally advanced vs distant metastases), surgery (radical prostatectomy vs none) and hormonal treatment type (anti-androgens plus aLHRH combination therapy vs aLHRH alone vs antiandrogens alone). Hardy-Weinberg equilibrium was tested using Pearson's w 2 -analysis to compare observed versus expected genotype frequencies.
We calculated the PAR, using the following formula: PAR ¼ PRF Â (1À1/OR). The PAR is the fraction of disease attributable to the risk factor, PRF is the percentage of the risk factor in case subjects, and OR is the odds ratio. All analyses were performed with SPSS 15.0 statistical software (SPSS Inc., Chicago, IL, USA) considering a level of significance o0.05. 
